Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05830214
Other study ID # Pro00125737
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date January 2024
Est. completion date February 6, 2024

Study information

Verified date February 2024
Source University of Alberta
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This observational study will use new smartwatch technology to continuously and remotely monitor the health of ALS patients and healthy controls over time. This information will be used to develop digital biomarkers for ALS.


Description:

This is an optional study that is conducted in parallel to CAPTURE ALS (NCT05204017). In this exploratory, prospective, longitudinal study, CAPTURE ALS participants undergo remote physiological data collection using smartwatch technology. Participants will wear a specialized smartwatch (Health Gauge AI-Based Wearable Device ) for the duration of the study. ALS patients will be followed for 12 months, healthy controls will be followed for 8 months. Digital questionnaires will monitor participant-related outcomes bi-monthly. Gait assessments will be performed by ambulatory patients and healthy controls in clinic during CAPTURE ALS study visits to measure changes in walking activity.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 6, 2024
Est. primary completion date February 6, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility [PATIENTS] Inclusion Criteria: - Has ALS, classified as definite, probable, laboratory-supported probable, or possible ALS according to the revised El Escorial criteria or a related neurodegenerative disorder including ALS-FTD, PLS, PMA or asymptomatic individuals with a known ALS mutation (as previously confirmed during the individual's regular clinical care) - Is the age of majority in their province of residence/treatment - Has the cognitive capacity to provide informed consent - Has proficiency in English or French in order to understand study instructions and respond to questionnaires Exclusion Criteria: - Is pregnant - Has a history of active (clinically significant) skin disorders - Has a history of allergic response to plastic materials - Has an electronic implant of any kind (e.g. pacemaker) - Has broken, damaged or irritated skin or rashes near the sensor application sites - Is unstably housed or lack reliable contact information. - Investigator judges that device retrieval will be difficult or unlikely - Does not have a smartphone that will support the HG application - Does not have daily access to a wireless connection [HEALTHY CONTROLS] Inclusion Criteria: - Be between the ages of 40-80 unless age matched to a patient (+/-3 years) who is already enrolled. - Is the age of majority in their province of residence/treatment - Has the cognitive capacity to provide informed consent - Has proficiency in English or French in order to understand study instructions and respond to questionnaires Exclusion Criteria: - Has a history of a neurological disease, including Central Nervous System disease (e.g., stroke, head injury, epilepsy) or Peripheral Nervous System disease (neuropathy, myopathy). - Has a history of psychiatric disease (e.g., depression, bipolar disease) that is clinically diagnosed and/or with the current use of psychiatric medications (e.g., antidepressants) for an indication of a psychiatric disease. - Is pregnant - Has a history of active (clinically significant) skin disorders - Has a history of allergic response to plastic materials - Has an electronic implant of any kind (e.g. pacemaker) - Has broken, damaged or irritated skin or rashes near the sensor application sites - Is unstably housed or lack reliable contact information. - Investigator judges that device retrieval will be difficult or unlikely - Does not have a smartphone that will support the HG application - Does not have daily access to a wireless connection

Study Design


Locations

Country Name City State
Canada University of Alberta Edmonton Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Body Temperature Body temperature in Degrees Celsius as measured by the Health Gauge smartwatch worn by the participant Up to 1 year
Primary Respiratory rate Respiratory rate in breaths per minute as measured by the Health Gauge smartwatch worn by the participant Up to 1 year
Primary Oxygen saturation Oxygen saturation in percent as measured using the Health Gauge smartwatch worn by participants Up to 1 year
Primary Heart rate Heart rate in beats per minute as measured using the Health Gauge smartwatch worn by participants Up to 1 year
Primary Step count Physical activity in step count as measured using the Health Gauge smartwatch worn by participants Up to 1 year
Primary Distance travelled Physical activity in distance travelled (meters) as measured using the Health Gauge smartwatch worn by participants Up to 1 year
Primary Calories Physical activity in calories as measured using the Health Gauge smartwatch worn by participants Up to 1 year
Primary Sleep stage Sleep stage in time in wake, light and deep stages as measured using the Health Gauge smartwatch worn by participants Up to 1 year
Secondary Timed Up and Go (TUG) The TUG is used to assess changes in functional mobility. Participants arise from a chair, walk forward 3 meters, turn around, walk back to the chair and sit. The time to complete the test is measured. Baseline
Secondary Timed Up and Go (TUG) The TUG is used to assess changes in functional mobility. Participants arise from a chair, walk forward 3 meters, turn around, walk back to the chair and sit. The time to complete the test is measured. Month 4
Secondary Timed Up and Go (TUG) The TUG is used to assess changes in functional mobility. Participants arise from a chair, walk forward 3 meters, turn around, walk back to the chair and sit. The time to complete the test is measured. Month 8
Secondary Timed Up and Go (TUG) The TUG is used to assess changes in functional mobility. Participants arise from a chair, walk forward 3 meters, turn around, walk back to the chair and sit. The time to complete the test is measured. Month 12
Secondary 10 Meter Walk The 10 Meter Walk Test is a performance measure used to assess walking speed over a short distance. This task will be performed with and without serial 3s subtraction. The time to walk 10 meters and the number of errors in the mental task are measured. Baseline
Secondary 10 Meter Walk The 10 Meter Walk Test is a performance measure used to assess walking speed over a short distance. This task will be performed with and without serial 3s subtraction. The time to walk 10 meters and the number of errors in the mental task are measured. 4 Months
Secondary 10 Meter Walk The 10 Meter Walk Test is a performance measure used to assess walking speed over a short distance. This task will be performed with and without serial 3s subtraction. The time to walk 10 meters and the number of errors in the mental task are measured. 8 Months
Secondary 10 Meter Walk The 10 Meter Walk Test is a performance measure used to assess walking speed over a short distance. This task will be performed with and without serial 3s subtraction. The time to walk 10 meters and the number of errors in the mental task are measured. 12 Months
Secondary 2-Minute Timed Walk Test (2MWT) The 2MWT assess overall gait function and endurance. The total distance travelled in 2 minutes is measured. Baseline
Secondary 2-Minute Timed Walk Test (2MWT) The 2MWT assess overall gait function and endurance. The total distance travelled in 2 minutes is measured. 4 Months
Secondary 2-Minute Timed Walk Test (2MWT) The 2MWT assess overall gait function and endurance. The total distance travelled in 2 minutes is measured. 8 Months
Secondary 2-Minute Timed Walk Test (2MWT) The 2MWT assess overall gait function and endurance. The total distance travelled in 2 minutes is measured. 12 Months
Secondary Changes in ALS Assessment Questionnaire (ALSAQ-40) Mobility Sub-score Changes in self-reported physical mobility over 1 year as measured using the ALSAQ-40 mobility sub-score, lower scores indicate better mobility. Changes from baseline at 1 year
Secondary Changes in Generalized Anxiety Disorder 7 (GAD-7) score Changes in self-reported anxiety over 1 year as measured using the GAD-7. The total score for the 7 items ranges from 0-21, with 0-4 (none to minimal anxiety), 5-9 (mild anxiety), 10-14 (moderate anxiety), 15-21 (severe anxiety). Changes from baseline at 1 year
Secondary Changes in ALSFRS-R Dyspnea and Orthopnea sub-scores Changes in self-reported dyspnea and orthopnea over 1 year as measured using the ALS Functional Rating Scale dyspnea and orthopnea sub-scores. Each question is scored by the participant as "4" (never) to "0" (all of the time). Changes from baseline at 1 year
Secondary Changes in Patient Health Questionnaire (PHQ-9) score Changes in self-reported depression over 1 year as measured using the PHQ-9. The total score for the 9 items ranges from 0-27, with 0-4 (none-minimal depression), 5-9 (mild depression), 10-14 (moderate depression), 15-19 (moderately severe depression), 20-27 (severe). Changes from baseline at 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1